ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Based on recent data, Horizon Therapeutics Public Limited Company (HZNP) shows an Average True Range (ATR) of N/A and an Enterprise Value of N/A. Its average trading volume over the past 3 months is N/A, indicating liquidity. These fundamental metrics provide insight into HZNP's underlying financial health and market activity.
Horizon Therapeutics Public Limited Company (HZNP) technical indicators as of August 15, 2025: the SMA 20 is N/A, SMA 50 at N/A, and SMA 200 at N/A. The RSI 14 value is N/A, suggesting its current momentum. These technical analysis signals help assess HZNP's price trends and potential future movements.
Horizon Therapeutics Public Limited Company (HZNP) stock performance overview as of August 15, 2025: The 52-week high is $116.3 (currently N/A below), and the 52-week low is $116.3 (currently N/A above). Over the past year, HZNP's performance is 78.7%, compared to the S&P 500's 16.68% change.
According to market data, Horizon Therapeutics Public Limited Company (HZNP) stock's recent performance metrics show that over the last month, HZNP is 15.18%, with a Year-to-Date (YTD) performance of 53.18%. Over the past year, the stock has seen a 78.7% change. These figures summarize HZNP's price movements across various periods, reflecting its historical returns.
According to current financial data, HZNP stock's P/E (TTM) ratio is 51.10, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for HZNP, including P/S (7.33), P/B (5.25), and P/FCF (23.51), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep